Aptevo Therapeutics (APVO) Deferred Taxes (2016 - 2017)
Historic Deferred Taxes for Aptevo Therapeutics (APVO) over the last 3 years, with Q4 2017 value amounting to -$7.5 million.
- Aptevo Therapeutics' Deferred Taxes rose 5107.44% to -$7.5 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$23.3 million, marking a year-over-year decrease of 4728.46%. This contributed to the annual value of -$2000.0 for FY2017, which is 9998.74% up from last year.
- As of Q4 2017, Aptevo Therapeutics' Deferred Taxes stood at -$7.5 million, which was up 5107.44% from -$15.3 million recorded in Q4 2016.
- In the past 5 years, Aptevo Therapeutics' Deferred Taxes registered a high of -$11000.0 during Q2 2016, and its lowest value of -$15.3 million during Q4 2016.
- Over the past 3 years, Aptevo Therapeutics' median Deferred Taxes value was -$575000.0 (recorded in 2015), while the average stood at -$4.0 million.
- As far as peak fluctuations go, Aptevo Therapeutics' Deferred Taxes plummeted by 219550.22% in 2016, and later skyrocketed by 5107.44% in 2017.
- Aptevo Therapeutics' Deferred Taxes (Quarter) stood at -$667000.0 in 2015, then plummeted by 2195.5% to -$15.3 million in 2016, then soared by 51.07% to -$7.5 million in 2017.
- Its last three reported values are -$7.5 million in Q4 2017, -$15.3 million for Q4 2016, and -$483000.0 during Q3 2016.